Prophylactic blood component therapy, “A saviour for obstetric patients at high risk for coagulopathy

Background: Prophylactic blood component therapy, “A saviour for obstetric patients with non overt DIC”. {Dr Neena Gupta, Dr Shaily Agarwal, Dr Apurva Agarwal, Uruj jahan,Fatima Usmani, Poonam) Aims: To evaluate the role of prophylactic blood component therapy in nonovert DIC patients to reduce maternal morbidity and mortality. Methodology: This study was conducted on total 274indoor obstetric patients in the Department of Obstetrics & Gynaecology of UISEMH Kanpur from January 2016 to August 2017. Results: In Group IB, majority were managed in ward (72.41%) only 13.79 % patients required ICU care but mortality was nil. While in group IA 20.63% needed ICU care and mortality was 1.59%. In group II (overt DIC) all required ICU care and mortality was 59.38%. Patients in group IB (prophylactic blood component therapy) had shorter duration of hospital stay as compared to group IA and II. 40.18% in group II (overt DIC), 33.92% in group IA and 6.92 % in group IB patients had hospital stay for more than 10 days. Conclusion: Prophylactic blood component therapy corrected the coagulation abnormality and prevented them from landing up into established DIC.